219 related articles for article (PubMed ID: 26765450)
21. Clinical Practices and Outcomes on Chemotherapy-Induced Nausea and Vomiting Management in South Korea: Comparison with Asia-Pacific Data of the Pan Australasian Chemotherapy Induced Emesis Burden of Illness Study.
Lee MA; Cho EK; Oh SY; Ahn JB; Lee JY; Thomas B; Jung H; Kim JG
Cancer Res Treat; 2016 Oct; 48(4):1420-1428. PubMed ID: 26875197
[TBL] [Abstract][Full Text] [Related]
22. Nomogram for Predicting Chemotherapy-Induced Nausea and Vomiting for Breast Cancer Patients.
Huang XJ; Li XY; Li JH; Hu ZY; Luo L; Tan Y; Chen HY; Fan RR; Wang TY; Meng LQ; Wei T
Tohoku J Exp Med; 2021 Jun; 254(2):111-121. PubMed ID: 34162779
[TBL] [Abstract][Full Text] [Related]
23. A prospective observational study on chemotherapy-induced nausea and vomiting (CINV) in patients with gynecologic cancer by the CINV Study Group of Japan.
Mizuno M; Hiura M; Kikkawa F; Numa F; Yaegashi N; Narahara H; Aoki D; Kimura E; Kato H; Shimokawa M; Sugiyama T; Kamura T
Gynecol Oncol; 2016 Mar; 140(3):559-64. PubMed ID: 26748216
[TBL] [Abstract][Full Text] [Related]
24. Analysis of aprepitant for prevention of chemotherapy-induced nausea and vomiting with moderately and highly emetogenic chemotherapy.
Molassiotis A; Nguyen AM; Rittenberg CN; Makalinao A; Carides A
Future Oncol; 2013 Oct; 9(10):1443-50. PubMed ID: 23987791
[TBL] [Abstract][Full Text] [Related]
25. The incidence of nausea in the absence of vomiting in patients receiving intravenous chemotherapy.
Smit T; Kotze I; du Plessis J
Ann Palliat Med; 2021 Mar; 10(3):2679-2686. PubMed ID: 33549001
[TBL] [Abstract][Full Text] [Related]
26. Prevalence and predictors of long-delayed (> 120 h) chemotherapy-induced nausea and vomiting (CINV)-a systematic review and individual patient data meta-analysis.
Chow R; Yin LB; Baqri W; Huang R; Boldt G; Younus J; Lock M; Prsic E; Zimmermann C; Herrstedt J
Support Care Cancer; 2023 Aug; 31(8):505. PubMed ID: 37535218
[TBL] [Abstract][Full Text] [Related]
27. Likelihood of a subsequent chemotherapy-induced nausea and vomiting (CINV) event in patients receiving low, moderately or highly emetogenic chemotherapy (LEC/MEC/HEC).
Schwartzberg L; Szabo S; Gilmore J; Haislip S; Jackson J; Jain G; Balu S; Buchner D
Curr Med Res Opin; 2011 Apr; 27(4):837-45. PubMed ID: 21309647
[TBL] [Abstract][Full Text] [Related]
28. 5-Hydroxytryptamine-3 receptor antagonist and dexamethasone as prophylaxis for chemotherapy-induced nausea and vomiting during moderately emetic chemotherapy for solid tumors: a multicenter, prospective, observational study.
Matsui R; Suzuki K; Takiguchi T; Nishio M; Koike T; Hayashi T; Seto T; Kogure Y; Nogami N; Fujiwara K; Kaneda H; Harada T; Shimizu S; Kimura M; Kenmotsu H; Shimokawa M; Goto K
BMC Pharmacol Toxicol; 2020 Oct; 21(1):72. PubMed ID: 33023657
[TBL] [Abstract][Full Text] [Related]
29. Delayed nausea and vomiting continue to reduce patients' quality of life after highly and moderately emetogenic chemotherapy despite antiemetic treatment.
Bloechl-Daum B; Deuson RR; Mavros P; Hansen M; Herrstedt J
J Clin Oncol; 2006 Sep; 24(27):4472-8. PubMed ID: 16983116
[TBL] [Abstract][Full Text] [Related]
30. Risk factors associated with chemotherapy-induced nausea and vomiting in the triplet antiemetic regimen including palonosetron or granisetron for cisplatin-based chemotherapy: analysis of a randomized, double-blind controlled trial.
Tsuji D; Suzuki K; Kawasaki Y; Goto K; Matsui R; Seki N; Hashimoto H; Hama T; Yamanaka T; Yamamoto N; Itoh K
Support Care Cancer; 2019 Mar; 27(3):1139-1147. PubMed ID: 30094732
[TBL] [Abstract][Full Text] [Related]
31. Palonosetron versus other 5-HT(3) receptor antagonists for prevention of chemotherapy-induced nausea and vomiting in patients with cancer on chemotherapy in a hospital outpatient setting.
Balu S; Buchner D; Craver C; Gayle J
Clin Ther; 2011 Apr; 33(4):443-55. PubMed ID: 21635990
[TBL] [Abstract][Full Text] [Related]
32. Adherence to pediatric acute chemotherapy-induced nausea and vomiting guidelines in Canadian hospitals.
McKinnon K; Jupp J; Ghosh S; Digout C; Eason S; Romanick M
Pediatr Blood Cancer; 2019 Jan; 66(1):e27488. PubMed ID: 30318842
[TBL] [Abstract][Full Text] [Related]
33. Efficacy and safety of rolapitant for prevention of chemotherapy-induced nausea and vomiting over multiple cycles of moderately or highly emetogenic chemotherapy.
Rapoport B; Schwartzberg L; Chasen M; Powers D; Arora S; Navari R; Schnadig I
Eur J Cancer; 2016 Apr; 57():23-30. PubMed ID: 26851398
[TBL] [Abstract][Full Text] [Related]
34. Randomized phase III trial of APF530 versus palonosetron in the prevention of chemotherapy-induced nausea and vomiting in a subset of patients with breast cancer receiving moderately or highly emetogenic chemotherapy.
Boccia R; O'Boyle E; Cooper W
BMC Cancer; 2016 Feb; 16():166. PubMed ID: 26921245
[TBL] [Abstract][Full Text] [Related]
35. Impact of 5-HT(3) RA selection within triple antiemetic regimens on uncontrolled highly emetogenic chemotherapy-induced nausea/vomiting.
Schwartzberg L; Jackson J; Jain G; Balu S; Buchner D
Expert Rev Pharmacoecon Outcomes Res; 2011 Aug; 11(4):481-8. PubMed ID: 21711119
[TBL] [Abstract][Full Text] [Related]
36. Comparison of two different intravenous serotonin antagonists used for chemotherapy-induced nausea and vomiting prophylaxis in patients treated with moderately emetogenic risk regimens: A retrospective analysis from a large academic medical center.
Gamble M; Carroll E; Wright GC; Glode AE
J Oncol Pharm Pract; 2020 Dec; 26(8):1964-1969. PubMed ID: 32633661
[TBL] [Abstract][Full Text] [Related]
37. Guideline concordant care for prevention of acute chemotherapy-induced nausea and vomiting in children, adolescents, and young adults.
Beauchemin M; Sung L; Hershman DL; Weng C; Dupuis LL; Schnall R
Support Care Cancer; 2020 Oct; 28(10):4761-4769. PubMed ID: 31974769
[TBL] [Abstract][Full Text] [Related]
38. Chemotherapy-induced nausea and vomiting and antiemetic prophylaxis with palonosetron versus other 5-HT3 receptor antagonists in patients with cancer treated with low emetogenic chemotherapy in a hospital outpatient setting in the United States.
Schwartzberg L; Morrow G; Balu S; Craver C; Gayle J; Cox D
Curr Med Res Opin; 2011 Aug; 27(8):1613-22. PubMed ID: 21696263
[TBL] [Abstract][Full Text] [Related]
39. Chemotherapy-induced nausea and vomiting in daily clinical practice: a community hospital-based study.
Hilarius DL; Kloeg PH; van der Wall E; van den Heuvel JJ; Gundy CM; Aaronson NK
Support Care Cancer; 2012 Jan; 20(1):107-17. PubMed ID: 21258948
[TBL] [Abstract][Full Text] [Related]
40. Chemotherapy-induced nausea and vomiting: incidence and characteristics of persistent symptoms and future directions NCCTG N08C3 (Alliance).
Kottschade L; Novotny P; Lyss A; Mazurczak M; Loprinzi C; Barton D
Support Care Cancer; 2016 Jun; 24(6):2661-7. PubMed ID: 26768436
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
